

Prognostic factors associated with survival and recurrence in resectable gastroesophageal adenocarcinoma: retrospective analysis of 497 patients operated at two Italian centers.

Authors:

Michele Ghidini, Andrea Botticelli, Bianca Maria Donida, Lidia Strigari, Concetta Elisa Onesti, Margherita Ratti, Claudio Pizzo, Federico Aldighieri, Laura Toppo, Valerio Ranieri, Mario Occhipinti, Chiara Senti, Giulia Tanzi, Federica Mazzuca, Paolo Marchetti, Mario Martinotti, Rodolfo Passalacqua, Gianluca Tomasello, Massimo Rovatti; Oncology Unit, Oncology Department, ASST of Cremona, Cremona, Italy; Department of Clinical and Molecular Medicine, Sapienza University Sant' Andrea Hospital, Rome, Italy; Laboratory of Medical Physics and Expert System, Sapienza University of Rome, Sant'Andrea Hospital, Rome, Italy; General Surgery Unit, Surgical Department, Assistant of Cremona, Cremona, Italy; Division of Oncology, ASST Cremona, Cremona, Italy; Pathology Unit, Laboratory department, ASST of Cremona, Cremona, Italy

[View Less](#)

[Abstract Disclosures](#)

Background:

Chemotherapy (CT) and chemoradiotherapy (CRT) both in neoadjuvant (neoadj) or adjuvant (adj) setting are associated with better overall survival (OS) over surgery alone in patients (pts) with resectable gastroesophageal (GE) adenocarcinoma (ADK). The best sequence and timing of treatments have still not been defined. A large cohort of GE ADKs derived from 2 high-volume Italian centers was analyzed to describe clinical outcomes and prognostic factors.

Methods:

497 patients (pts) diagnosed with GE ADK who underwent surgery with curative intent from 2007 to 2016 were considered. Variables analyzed were: age, sex, tumor location, histology, T, N, M, R, G, HER-2, Helicobacter Pylori (HP) infection, (neo)adj CT, and adj CRT. Analysis was performed according to ITT principle.

Results:

Median age at diagnosis was 71 years (range 35-92). At 26.7 months (mo) median follow-up, median OS was 27.6 mo (range 1-127) and median time to recurrence (TTR) 10.8 mo (range 7.8-13.1). Adj CT was administered in 203 cases (41%); 116 pts (23%) had adj CRT and 47 (9%) neoadj CT. Statistically significant variables for OS and/or TTR at 12 months at univariate analysis were: age, T, N, M, R, G, adj CRT, neoadj CT and adj CT. Results of multivariate analysis (MVA) are shown in Table 1.

Conclusions:

Despite a short follow-up, our analysis performed on a very large cohort of consecutive pts confirms the prognostic value of T and N for both OS and TTR. Adj CT and CRT had a significant impact on 1 year OS, while neoadj CT gave only a 12 months TTR significant benefit. Based on these results, perioperative treatment strategies should always be considered in the management of resectable GE cancer.

1 MVA for OS and RFS

Variable	OS at 12 months (p value)	TTR at 12 months (p value)
T (4 vs 0-3)	<0.001*	1.28 10 ⁻⁵ *
N (0 vs 1 vs 2 vs 3)	<0.001*	3.91 10 ⁻⁴ *
M (0 vs 1)	n.s.	n.s.
R (0 vs 1 vs 2)	0.03*	n.s.
G (3-4 vs 1-2)	n.s.	n.s.
Adj CRT (no vs yes)	0.0028*	n.s.
Neoadj CT (no vs yes)	n.s.	0.0062*
Adj CT (no vs yes)	0.003*	n.s.

* : statistically significant; n.s. : not significant Age, sex, tumor location, histology, HER-2 and HP status: n.s. at MVA

